15 / 19
allied
academies
Page 43
Notes:
September 09-10, 2019 | Edinburgh, Scotland
2
nd
Global Summit on
3
rd
International Conference on
Dermatology and Cosmetology
Wound Care, Tissue Repair and Regenerative Medicine
Joint Event
&
Journal of Dermatology Research and Skin Care | Volume 3
Dermatol Res Skin Care, Volume 3
Psoriasis - Newmethods of treatment
Dominika Bielinska-Warezak
Accelerated Enrollment Solutions, Poland
P
soriasis is the most prevalent immune-mediated skin
disease that affects 1%to3%of thepopulationworldwide,
with an equal sex distribution and it can be presented in
any age. The most common form of the disease is plaque
psoriasis observed in more than 80% of psoriasis patients.
Approximately 17% of those with psoriasis have moderate to
severe disease. Psoriasis causes a high degree of morbidity
and decreased quality of life. A number of comorbidities
have been associated with psoriasis. Psoriasis arthritis,
cardiovascular disease, metabolic syndrome, renal disease
and diabetes have been demonstrated to have an increased
prevalence. Psoriasis treatment varies with the extent and
severity of the disease. Limited or mild disease is treated with
topicaltherapiessuchascorticosteroidsandvitaminDanalogs.
For more resistant or moderate to severe disease systemic
oral, parenteral medications and phototherapy are used for
better effficacy. Standard therapies for psoriasis are: topical
steroids, vitamin D analogs, phototherapy, methotrexate,
cyclosporine, apremilast and biologics including TNFα
inhibitors, IL-12/23 inhibitors, the IL-23p19 antagonist, IL-
17A inhibitors, these products are the treatment options of
choice for patients with moderate to severe plaque psoriasis
who are candidates for systemic therapy or phototherapy.
These drugs are injected sc or delivered via intravenous (iv)
infusion. Many methods of treatment are associated with
increased risk of adverse events such as hepatotoxicity and
neutropenia, nephrotoxicity, depression, weight loss, serious
infections, candidiasis, Crohn’s disease. Many patients with
severe disease are still managed with only topicals and
consider their treatment to be inadequate. Different from
traditional systemic drugs that impact the entire immune
system, biologics target specific parts of the immune system
and offer reduced multi-organ toxicity and adverse effects.
Accordingly, there remains a need for more effective options,
when compared with currently available agents, that would
improve efficacy responses and increase adherence to
treatment.
Speaker Biography
Dominika Bielinska-Warezak is consultant dermatologist with over 20 years
of experience. She is Principal Investigator Phase II and III of clinical trials
in Accelerated Enrollment Solutions, works as Clinical Research Physician
in numerous trials with psoriatic patients. She has graduated fromMedical
University of Gdansk with 5 clinical clerkships at Department of General
Dermatology of University of Vienna, Universidad de Malaga, Lund
University, Meridia South Pointe Hospital, Cleveland, Ohio and University
of Gronigen.
e:
bieldom1@o2.pl